Analysts are on the Bearish side about Atara Biotherapeutics, Inc

Tuesday, 17 Apr, 2018

The firm earned "Market Outperform" rating on Tuesday, December 15 by JMP Securities. The company was maintained on Monday, December 7 by Cantor Fitzgerald. (NASDAQ:ATRA) on Wednesday, November 18 with "Neutral" rating. This short time frame picture represents an upward movement of current price over average price of last 20 days. They set an "overweight" rating and a $56.00 target price for the company. The company was reinitiated on Thursday, June 22 by Jefferies. The company was maintained on Thursday, September 21 by Cantor Fitzgerald. (NASDAQ:ATRA). Goldman Sachs Gp Inc accumulated 20,266 shs. Over the past twelve months, Atara Biotherapeutics, Inc. BidaskClub lowered Atara Biotherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 3rd.

The company is estimating to achieve earnings per share (EPS) growth of -45.40% in this year and the earnings per share (EPS) growth expected to be -10.80% in the next year. (NASDAQ:ATRA). State Of Wisconsin Inv Board stated it has 0% of its capital in Atara Biotherapeutics, Inc. It has outperformed by 77.18% the S&P500.

Since January 1, 0001, it had 0 buys, and 21 insider sales for $14.32 million activity. In Thursday, February 15 report Citigroup downgraded the stock to "Sell" rating. Great West Life Assurance Company Can holds 0% or 1,654 shares. Insiders sold a total of 315,324 shares of company stock valued at $11,379,838 over the last quarter. About 240,170 shares traded. (NASDAQ:ATRA). Hudson Bay Mgmt Ltd Partnership has invested 0.01% in Atara Biotherapeutics, Inc. Therefore 60% are positive. ITT Corp had 33 analyst reports since September 1, 2015 according to SRatingsIntel. The stock has "Buy" rating by Jefferies on Monday, March 5. The stock rating was maintained by William Blair with "Buy" on Friday, April 6.

2/6/2018 - Atara Biotherapeutics was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. William Blair initiated the shares of ATRA in report on Friday, October 9 with "Outperform" rating. Canaccord Genuity maintained Atara Biotherapeutics, Inc. On Wednesday, January 3 the company was upgraded by Citigroup. On Wednesday, February 28 the rating was downgraded by JMP Securities to "Market Perform". Shares for $3.80 million were sold by Clark Mitchall G. Gallagher Carol Giltner sold $55,010 worth of Atara Biotherapeutics, Inc. Citigroup upgraded Atara Biotherapeutics, Inc. On Tuesday, April 10 the firm has "Buy" rating given by J.P. Morgan. They set a "neutral" rating on the stock.

Big Money Sentiment decreased to 1.42 in 2017 Q4. A total of 0.73 million shares exchanged at hands and its average trading volume is standing at 0.96 million shares. Shares of Atara Biotherapeutics, Inc. Dimensional Fund Advisors LP grew its stake in shares of Atara Biotherapeutics by 2.9% during the 2nd quarter. Grp Inc holds 0% or 18,016 shares. Schwab Charles Incorporated accumulated 0% or 104,612 shares. 25,000 were reported by Pacific Heights Asset Ltd Llc. (NASDAQ:ATRA). Indexiq Advisors Limited Liability Corp holds 0.05% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 937,492 shares. Camber Capital Ltd Liability accumulated 535,500 shs. Eagle Asset Inc holds 0.16% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was sold by Haqq Christopher on Monday, October 16. New York-based Retail Bank Of Ny Mellon has invested 0% in Atara Biotherapeutics, Inc.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, February 27th. 1 funds opened positions while 0 raised stakes.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States.The company has $1.75 billion market cap. The company has a market cap of $1,541.39, a PE ratio of -10.05 and a beta of 2.59. The Company's clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus.